All In Biotech

Drug Trial Radar · NCT04947631

Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia

A Multi-center, Randomized, Double-blinded, Double-dummy, Parallel Group, 48-week, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia

Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 667 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

667

Actual

Start

Jul 27, 2021

Primary completion

Jun 12, 2023

Study completion Jun 12, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients with benign prostatic hyperplasia.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • DKF-313Drug

    Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks

  • DutasterideDrug

    Dutasteride 0.5 mg once daily for 48 weeks

  • TadalafilDrug

    Tadalafil 5 mg once daily for 48 weeks

  • DKF-313 placeboDrug

    Once daily for 48 weeks

  • Dutasteride placeboDrug

    Once daily for 48 weeks

  • Tadalafil placeboDrug

    Once daily for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Total International Prostate Symptom Score (IPSS) from baseline to Week 48Time frame: Weeks 0 and 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ewha Womans University mokdong Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.